Driehaus Capital Management LLC Immuno Gen, Inc. Transaction History

Driehaus Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $15.5 Million - $37.3 Million	-1,244,072 Reduced 86.39%	195,980 $5.81 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $3.72 Million - $5.24 Million	263,922 Added 22.44%	1,440,052 $22.9 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $4.41 Million - $23.6 Million	1,176,130 New	1,176,130 $22.2 Million
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $254,863 - $466,035	80,909 Added 32.36%	330,909 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $1.19 Million - $1.88 Million	250,000 New	250,000 $1.86 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.